IBO PRESS-RELEASE SEC Filing Analysis

Latest settled — T+20d

IBO ▼ -0.78% at T+20d

SHORT call ✓ call won +0.78% · α vs SPY +9.76% · entry $0.6400 → $0.6350

Next anchor: T+60d in 15d

Last close $0.5850 (close Jun 12) · +8.59% from $0.6400 entry (call sign-flipped)

Entry anchored
Apr 2, 03:00 PM ET
via Databento tick

T+1d

+4.53%

call -4.53% · α -4.47%

$0.6690

settled 2mo ago

T+5d

+9.38%

call -9.38% · α -5.24%

$0.7000

settled 2mo ago

T+20d

-0.78%

call +0.78% · α +9.76%

$0.6350

settled 6w ago

T+60d

—

call — · α —

—

in 15d

Price Chart

Loading chart...

Executive Summary

Impact BioMedical (IBO) disclosed that its 2025 audit opinion includes a 'going concern' qualification, signaling substantial doubt about its ability to continue as a going concern. The company reiterated its planned merger with Dr. Ashley’s Ltd., expected by July 1, 2026, as part of its survival strategy.

Actionable Insight

Traders should monitor the progress of the Dr. Ashley’s Ltd. merger as the key catalyst for survival; absence of the deal or failure to secure financing likely triggers delisting or bankruptcy. Short-term downside risk is elevated given insider selling and lack of financial clarity.

Key Facts

Audit opinion for FY2025 includes a 'going concern' qualification from Grassi & Co., CPAs.
Disclosure made per NYSE American rules, confirming no change to the 10-K but affirming financial distress.
Company is pursuing a merger with Dr. Ashley’s Ltd., targeted for completion by July 1, 2026.
Recent insider selling: $58K in sales over the past 30 days by 3 insiders.

Financial Impact

Material uncertainty due to going concern; no specific financial figure disclosed but implies risk of insolvency without financing or merger.

liquiditydebtgoing_concernmarket_confidence

Risk Factors

Risk of delisting from NYSE American if going concern issues are not resolved.
Merger with Dr. Ashley’s Ltd. may not close due to regulatory, financing, or counterparty risk.
Further dilution or emergency financing likely if merger fails.

Market Snapshot

Exchange

NYSE

Sector

Pharmaceutical Preparations

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

Document	Accession Number
PRESS-RELEASE Data (Synthetic)	press-3268111

3 reports for IBO

T+1T+5T+20T+60

Track record builds as more directional reports settle.

Filters

Reports for IBO — sortable, filterable
	Type				Now
Apr 29, 2026 6w ago	144 BEARISH ★ 8/10	$0.6800 $0.5200	▲ +23.53%	▲ +28.76%	$0.5850 (+13.97%)
Apr 3, 2026 10w ago	Press Release BEARISH ★ 8/10	$0.6400 $0.6350	▲ +0.78%	▲ +9.76%	$0.5850 (+8.59%)
Mar 23, 2026 12w ago	Insider Cluster BEARISH ★ 4/10	$0.6470 $0.6980	▼ −7.88%	▼ −0.46%	$0.5850 (+9.58%)

US Market Status

Market Closed — Opens in 3h 16m

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access